Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer
Kymera Therapeutics (NASDAQ: KYMR) has appointed Noah Goodman, M.B.A., as Chief Business Officer to lead business development strategy and activities. Goodman brings extensive life sciences industry experience, having previously served as President and Chief Business Officer at Chroma Medicine and nChroma Bio through their merger with Nvelop Therapeutics.
Prior to joining Kymera, Goodman held key positions at several biotech companies, including Executive Director roles at Cadent Therapeutics (later acquired by Novartis) and Seres Therapeutics, where he led collaborations and licensing transactions. His earlier experience includes business development at Spark Therapeutics and consulting at Easton Associates.
The appointment aligns with Kymera's mission to develop oral small molecule degrader medicines for immunological diseases and build a fully integrated biopharmaceutical company.
Kymera Therapeutics (NASDAQ: KYMR) ha nominato Noah Goodman, M.B.A. come Chief Business Officer per guidare la strategia e le attività di sviluppo commerciale. Goodman porta con sé una vasta esperienza nel settore delle scienze della vita, avendo precedentemente ricoperto il ruolo di Presidente e Chief Business Officer presso Chroma Medicine e nChroma Bio durante la loro fusione con Nvelop Therapeutics.
Prima di unirsi a Kymera, Goodman ha ricoperto ruoli chiave in diverse aziende biotecnologiche, inclusi i ruoli di Direttore Esecutivo presso Cadent Therapeutics (successivamente acquisita da Novartis) e Seres Therapeutics, dove ha guidato collaborazioni e transazioni di licenza. La sua esperienza precedente include lo sviluppo commerciale presso Spark Therapeutics e consulenze presso Easton Associates.
Questa nomina è in linea con la missione di Kymera di sviluppare medicinali degradatori a piccole molecole orali per malattie immunologiche e costruire una compagnia biofarmaceutica completamente integrata.
Kymera Therapeutics (NASDAQ: KYMR) ha nombrado a Noah Goodman, M.B.A. como Director Comercial para liderar la estrategia y actividades de desarrollo empresarial. Goodman aporta una amplia experiencia en la industria de las ciencias de la vida, habiendo sido anteriormente Presidente y Director Comercial en Chroma Medicine y nChroma Bio durante su fusión con Nvelop Therapeutics.
Antes de unirse a Kymera, Goodman ocupó puestos clave en varias empresas biotecnológicas, incluidos roles de Director Ejecutivo en Cadent Therapeutics (más tarde adquirida por Novartis) y Seres Therapeutics, donde lideró colaboraciones y transacciones de licencias. Su experiencia anterior incluye el desarrollo empresarial en Spark Therapeutics y consultoría en Easton Associates.
El nombramiento está alineado con la misión de Kymera de desarrollar medicamentos degradadores orales a base de pequeñas moléculas para enfermedades inmunológicas y construir una empresa biofarmacéutica completamente integrada.
Kymera Therapeutics (NASDAQ: KYMR)는 Noah Goodman, M.B.A.를 최고 사업 책임자(Chief Business Officer)로 임명하여 사업 개발 전략 및 활동을 이끌게 했습니다. Goodman은 생명 과학 산업에서 광범위한 경험을 가지고 있으며, 이전에는 Chroma Medicine과 nChroma Bio의 사장 및 최고 사업 책임자로 재직하며 Nvelop Therapeutics와의 합병을 이끌었습니다.
Kymera에 합류하기 전, Goodman은 여러 생명공학 회사에서 주요 직책을 맡았으며, Cadent Therapeutics(후에 노바티스에 인수됨)와 Seres Therapeutics에서 임원 이사로서 협력 및 라이센스 거래를 이끌었습니다. 그의 이전 경험에는 Spark Therapeutics에서의 사업 개발과 Easton Associates에서의 컨설팅이 포함됩니다.
이번 임명은 면역 질환을 위한 경구용 소분자 분해제 의약품 개발과 완전 통합된 생명공학 회사를 구축하려는 Kymera의 사명과 일치합니다.
Kymera Therapeutics (NASDAQ: KYMR) a nommé Noah Goodman, M.B.A. au poste de Chief Business Officer pour diriger la stratégie et les activités de développement commercial. Goodman apporte une vaste expérience dans l'industrie des sciences de la vie, ayant précédemment été Président et Chief Business Officer chez Chroma Medicine et nChroma Bio lors de leur fusion avec Nvelop Therapeutics.
Avant de rejoindre Kymera, Goodman a occupé des postes clés dans plusieurs entreprises biotechnologiques, notamment en tant que Directeur Exécutif chez Cadent Therapeutics (ultérieurement acquis par Novartis) et Seres Therapeutics, où il a dirigé des collaborations et des transactions de licence. Son expérience antérieure inclut le développement commercial chez Spark Therapeutics et le conseil chez Easton Associates.
Cette nomination s'inscrit dans la mission de Kymera de développer des médicaments dégradants à petites molécules orales pour les maladies immunologiques et de construire une entreprise biopharmaceutique totalement intégrée.
Kymera Therapeutics (NASDAQ: KYMR) hat Noah Goodman, M.B.A. zum Chief Business Officer ernannt, um die Strategie und Aktivitäten der Geschäftsentwicklung zu leiten. Goodman bringt umfangreiche Erfahrungen aus der Lebenswissenschaftsbranche mit, da er zuvor als Präsident und Chief Business Officer bei Chroma Medicine und nChroma Bio tätig war und die Fusion mit Nvelop Therapeutics leitete.
Vor seinem Eintritt bei Kymera hatte Goodman Schlüsselpositionen in mehreren Biotech-Unternehmen inne, darunter als Executive Director bei Cadent Therapeutics (später von Novartis übernommen) und Seres Therapeutics, wo er Kooperationen und Lizenztransaktionen leitete. Zu seinen früheren Erfahrungen gehört die Geschäftsentwicklung bei Spark Therapeutics und die Beratung bei Easton Associates.
Die Ernennung steht im Einklang mit Kymeras Mission, orale kleine Molekül-Degrader-Medikamente für immunologische Krankheiten zu entwickeln und ein vollständig integriertes biopharmazeutisches Unternehmen aufzubauen.
- Strategic hire with extensive business development and merger experience
- Addition strengthens leadership team for clinical development and commercialization phase
- None.
WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Mr. Goodman brings a wealth of diverse experience in the life sciences industry to Kymera and will lead business development strategy and activities for the company.
“We continue to stay focused on our mission of building a fully integrated biopharmaceutical company focused on discovering and developing oral drugs with biologics-like activity,” said Nello Mainolfi, Ph.D., Founder, President and CEO, Kymera Therapeutics. “Noah’s demonstrated leadership and business acumen will support Kymera’s continued growth as we advance our expanding pipeline through clinical development and eventual commercialization.”
“Kymera’s approach has exceptionally broad utility with the opportunity to transform existing treatment paradigms for millions of patients suffering from debilitating diseases,” said Mr. Goodman. “I’m thrilled to join the team during such an exciting time of growth and progress and look forward to realizing the full potential and impact of our industry-leading portfolio.”
Before joining Kymera, Mr. Goodman held senior leadership roles at Chroma Medicine and nChroma Bio, serving as President and Chief Business Officer through the merger with Nvelop Therapeutics. He also served as Executive Director and Head of Business Development at Cadent Therapeutics, which was subsequently acquired by Novartis, and Seres Therapeutics, where he was responsible for leading collaborations and licensing transactions across several therapeutic areas. Earlier in his career, Mr. Goodman also worked in business development at Spark Therapeutics and served as a management consultant at Easton Associates, a boutique life sciences consultancy. He holds a B.S. in neuroscience from the University of Michigan and an M.B.A. from the Wharton School of the University of Pennsylvania.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Availability of Other Information About Kymera Therapeutics
For more information, please visit the Kymera website at https://www.kymeratx.com/ or follow Kymera on X (@KymeraTx) and LinkedIn (Kymera Therapeutics). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, and press releases, as well as on X and LinkedIn. The information that Kymera posts on its website or on X or LinkedIn could be deemed to be material information. As a result, the Company encourages investors, the media and others interested to review the information that Kymera posts there on a regular basis. The contents of Kymera’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
What is Noah Goodman's role at Kymera Therapeutics (KYMR)?
What is Kymera Therapeutics (KYMR) developing?
What was Noah Goodman's previous experience before joining KYMR?
What are Kymera Therapeutics' (KYMR) current business objectives?
